BRPI0808098A2 - 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso - Google Patents

4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso

Info

Publication number
BRPI0808098A2
BRPI0808098A2 BRPI0808098-4A2A BRPI0808098A BRPI0808098A2 BR PI0808098 A2 BRPI0808098 A2 BR PI0808098A2 BR PI0808098 A BRPI0808098 A BR PI0808098A BR PI0808098 A2 BRPI0808098 A2 BR PI0808098A2
Authority
BR
Brazil
Prior art keywords
naphthridinamids
hydro
aryl
replaced
naphthridinamids replaced
Prior art date
Application number
BRPI0808098-4A2A
Other languages
English (en)
Inventor
Lars Baerfacker
Peter Kolkhof
Karl-Heinz Schlemmer
Rolf Grosser
Adam Nitsche
Martina Klein
Klaus Muenter
Barbara Albrecht-Kuepper
Elke Hartmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39512753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0808098(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Priority to BR122020008544A priority Critical patent/BR122020008544B8/pt
Publication of BRPI0808098A2 publication Critical patent/BRPI0808098A2/pt
Publication of BRPI0808098B1 publication Critical patent/BRPI0808098B1/pt
Publication of BRPI0808098B8 publication Critical patent/BRPI0808098B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
BRPI0808098A 2007-02-27 2008-02-19 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, seu uso e seu processo de preparação, e medicamento BRPI0808098B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020008544A BR122020008544B8 (pt) 2007-02-27 2008-02-19 uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007009494.0 2007-02-27
DE102007009494A DE102007009494A1 (de) 2007-02-27 2007-02-27 Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
PCT/EP2008/001257 WO2008104306A2 (de) 2007-02-27 2008-02-19 Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridinamide und ihre verwendung

Publications (3)

Publication Number Publication Date
BRPI0808098A2 true BRPI0808098A2 (pt) 2014-06-17
BRPI0808098B1 BRPI0808098B1 (pt) 2020-08-04
BRPI0808098B8 BRPI0808098B8 (pt) 2021-05-25

Family

ID=39512753

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0808098A BRPI0808098B8 (pt) 2007-02-27 2008-02-19 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, seu uso e seu processo de preparação, e medicamento
BR122020008544A BR122020008544B8 (pt) 2007-02-27 2008-02-19 uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020008544A BR122020008544B8 (pt) 2007-02-27 2008-02-19 uso de 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas, e medicamento

Country Status (46)

Country Link
US (2) US8436180B2 (pt)
EP (1) EP2132206B1 (pt)
JP (2) JP5367586B2 (pt)
KR (1) KR101614164B1 (pt)
CN (1) CN101641352B (pt)
AR (1) AR065463A1 (pt)
AU (1) AU2008221071B2 (pt)
BR (2) BRPI0808098B8 (pt)
CA (1) CA2679232C (pt)
CL (1) CL2008000502A1 (pt)
CO (1) CO6220951A2 (pt)
CR (1) CR10976A (pt)
CU (1) CU23874B1 (pt)
CY (2) CY1116455T1 (pt)
DE (1) DE102007009494A1 (pt)
DK (1) DK2132206T3 (pt)
DO (1) DOP2009000205A (pt)
EC (1) ECSP099581A (pt)
ES (1) ES2540803T3 (pt)
FR (1) FR22C1017I2 (pt)
GT (1) GT200900230A (pt)
HN (1) HN2009001597A (pt)
HR (1) HRP20150702T1 (pt)
HU (2) HUE026441T2 (pt)
IL (1) IL200060A (pt)
JO (1) JO3018B1 (pt)
LT (1) LTC2132206I2 (pt)
LU (1) LUC00260I2 (pt)
MA (1) MA31245B1 (pt)
MX (1) MX2009008701A (pt)
MY (2) MY150748A (pt)
NL (1) NL301192I2 (pt)
NO (1) NO2022013I1 (pt)
NZ (1) NZ579230A (pt)
PA (1) PA8770101A1 (pt)
PE (1) PE20090724A1 (pt)
PL (1) PL2132206T3 (pt)
PT (1) PT2132206E (pt)
SA (1) SA08290071B1 (pt)
SI (1) SI2132206T1 (pt)
TN (1) TN2009000318A1 (pt)
TW (2) TWI415608B (pt)
UA (1) UA102065C2 (pt)
UY (3) UY38953A (pt)
WO (1) WO2008104306A2 (pt)
ZA (1) ZA200905730B (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP2932289A1 (en) * 2012-12-17 2015-10-21 General Electric Company In-vitro magnetic resonance detection of a target substance
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
CN103193704B (zh) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-羟基-4-氨基-5-甲基吡啶杂环化合物
RS58274B1 (sr) 2014-06-30 2019-03-29 Astrazeneca Ab Benzoksazinon amidi kao modulatori mineralokortikoidnog receptora
CN116655627A (zh) * 2014-08-01 2023-08-29 拜耳医药股份有限公司 一种化合物的制备方法及其纯化以用作活性药物成分
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN108473488A (zh) * 2015-08-21 2018-08-31 拜耳制药股份公司 (4s)-和(4r)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-甲酰胺的代谢物的制备方法及其用途
HRP20191476T1 (hr) * 2015-08-21 2019-11-15 Bayer Pharma AG Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6-naftiridin-3-karboksamida i povrat (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6-naftiridin-3-karboksamida elektrokemijskim postupcima
PT3337800T (pt) * 2015-08-21 2019-08-05 Bayer Pharma AG Método para a preparação de (4s)-4-(4-ciano-2-metoxi fenil)-5-etoxi-2,8-dimetil-1,4-di-hidro-1-6-naftiridina-3- carboxamida e purificação do mesmo para a utilização como ingrediente farmacêutico ativo
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
US10640497B2 (en) 2015-12-02 2020-05-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN109890379A (zh) * 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
JP7101688B2 (ja) 2016-10-11 2022-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト ｓＧＣ刺激薬とミネラルコルチコイド受容体拮抗薬とを含む組み合わせ
WO2018153898A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
US11447481B2 (en) 2017-06-02 2022-09-20 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
DE102017008472A1 (de) 2017-09-08 2018-05-03 Bayer Pharma Aktiengesellschaft Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten
CN109721536B (zh) * 2017-10-27 2020-11-24 广东东阳光药业有限公司 苯基取代的稠合三环类化合物及其用途
EP3560922A1 (de) 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
EP3798219A4 (en) * 2018-05-22 2022-02-09 Sunshine Lake Pharma Co., Ltd. PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUND AND USE THEREOF
CN110917195A (zh) * 2018-08-20 2020-03-27 山西惠尔健生物科技有限公司 肌松剂阿库氯铵（Alcuronium chloride）可作为抗心律失常药物
JP7562546B2 (ja) 2019-02-12 2024-10-07 ミルム ファーマシューティカルズ インコーポレイテッド 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法
MX2021010612A (es) 2019-03-05 2021-09-28 Bayer Ag Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermediario para la sintesis del antagonista mr finerenona) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermediario 2-cloro-5-metil-4-piridinamina.
CN113412255B (zh) 2019-03-05 2024-07-02 拜耳公司 制备4-氨基-5-甲基吡啶酮的方法
MX2022004480A (es) * 2019-10-17 2022-05-06 Bayer Ag Procedimiento para preparar esteres aciloximetilicos del acido (4s)-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6- naftiridin-3-carboxilico.
BR112022005899A2 (pt) 2019-10-17 2022-06-28 Bayer Ag Método fotoquímico para preparar (4r,4s)-4-(ciano-2-metoxifenil)-5-etoxi-2,8-dietil-1,4-dihidro-1,6-naftidirina-1,6-carboxamida
MX2022004467A (es) * 2019-10-17 2022-05-03 Bayer Ag Procedimiento para preparar (4s)-4-(4-ciano-2-metoxi-fenil)-5-etox i-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilato de 2-cianoetilo mediante separacion de racematos utilizando esteres diastereomericos de acido tartarico.
WO2021074072A1 (de) * 2019-10-17 2021-04-22 Bayer Aktiengesellschaft Verfahren zur herstellung von 2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylat durch racemat-spaltung mittels diastereomerer weinsäureester
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
US20230201174A1 (en) 2020-04-22 2023-06-29 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP3900722A1 (en) 2020-04-22 2021-10-27 Bayer AG Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
WO2021213493A1 (zh) * 2020-04-24 2021-10-28 东莞市东阳光新药研发有限公司 二氢萘啶类化合物的晶型及其用途
CN113549066B (zh) * 2020-04-24 2023-07-21 年衍药业(珠海)有限公司 二氢萘啶类化合物的晶型及其用途
TW202214624A (zh) 2020-06-16 2022-04-16 德商拜耳廠股份有限公司 藉由催化不對稱漢斯（ｈａｎｔｚｓｃｈ）酯還原法進行之製備（４ｓ）－４－（４－氰基－２－甲氧基苯基）－５－乙氧基－２，８－二甲基－１，４－二氫－１，６－㖠啶－３－羧醯胺的方法
WO2022214206A1 (en) 2021-04-08 2022-10-13 Bayer Aktiengesellschaft Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases
EP4373476A1 (en) * 2021-07-21 2024-05-29 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CA3231311A1 (en) * 2021-09-18 2023-03-23 Tuojie Biotech (Shanghai) Co., Ltd. Substituted 1,4-dihydro-1,6-naphthyridine amide and use thereof
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
US20250270184A1 (en) 2022-04-18 2025-08-28 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
EP4286368A1 (de) 2022-05-31 2023-12-06 Bayer Aktiengesellschaft Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril
WO2024022481A1 (zh) * 2022-07-29 2024-02-01 苏中药业集团股份有限公司 苯基取代的二氢萘啶类化合物及其制备与用途
CN116023377A (zh) * 2022-08-30 2023-04-28 杭州科巢生物科技有限公司 非奈利酮的制备方法及其关键手性中间体
WO2024094181A1 (zh) 2022-11-04 2024-05-10 南京威凯尔生物医药科技有限公司 通过非对映酒石酸酯拆分外消旋体制备非奈利酮的方法
EP4622646A1 (en) 2022-11-23 2025-10-01 Bayer Aktiengesellschaft Treatment of chronic kidney disease in type i diabetes mellitus
WO2024126694A1 (en) 2022-12-16 2024-06-20 Bayer Aktiengesellschaft Sequential one-pot synthesis for preparing 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
CN116082334B (zh) * 2023-01-12 2025-12-09 上海新礼泰药业有限公司 非奈利酮及其中间体的制备方法
CN116041347B (zh) * 2023-01-12 2025-12-09 上海新礼泰药业有限公司 非奈利酮中间体的制备方法
CN120731206A (zh) * 2023-03-17 2025-09-30 江苏恒瑞医药股份有限公司 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法
CN121399121A (zh) 2023-05-31 2026-01-23 Jw制药公司 制备非奈利酮的方法、非奈利酮的中间体化合物及制备所述中间体化合物的方法
CN116715664B (zh) * 2023-06-12 2025-01-17 常州制药厂有限公司 一种非奈利酮关键中间体的制备方法
CN119302952A (zh) * 2023-07-11 2025-01-14 苏中药业集团股份有限公司 含苯基取代的二氢萘啶类化合物的药物制剂与用途
CN120081840A (zh) * 2023-12-01 2025-06-03 山东诚创蓝海医药科技有限公司 一种非奈利酮-马来酸共晶及其制备方法
IT202300027735A1 (it) 2023-12-22 2025-06-22 Ind Chimica Srl Processo per la preparazione di (4s)-4-(4-ciano-2-metossifenil)-5-etossi-1,4-diidro-2,8-dimetil-1,6-naftiridina-3-carbossammide
US20250313559A1 (en) 2024-01-05 2025-10-09 Bayer Aktiengesellschaft Method of preventing or treating heart failure in a patient using (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
EP4691463A1 (en) 2024-08-05 2026-02-11 Bayer Aktiengesellschaft Finerenone for use in a method of preventing or treating heart failure in a patient receiving a cyp3a4 inhibitor or a cyp3a4 inducer
WO2025224069A1 (en) 2024-04-23 2025-10-30 Bayer Aktiengesellschaft Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors
WO2025247801A1 (en) 2024-05-30 2025-12-04 Bayer Aktiengesellschaft Determination of a dosage of a nonsteroidal mineralocorticoid receptor antagonist
WO2026013638A1 (en) * 2024-07-12 2026-01-15 Ami Lifesciences Private Limited A process for the preparation of finerenone and intermediates thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698341A (en) * 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
DE3502831A1 (de) 1985-01-29 1986-07-31 Gödecke AG, 1000 Berlin 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung
DE3327650A1 (de) 1983-07-30 1985-02-14 Gödecke AG, 1000 Berlin 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von gefaesserkrankungen
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3431303A1 (de) * 1984-08-25 1986-02-27 Goedecke Ag 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung
US4760081A (en) * 1984-08-25 1988-07-26 Goedecke Aktiengesellschaft 1,6-naphthyridine derivatives useful for treating diseases of the blood vessels
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
CA2385908A1 (en) 2000-08-02 2002-02-07 Abbott Laboratories Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
DE102004012365A1 (de) 2004-03-13 2005-09-29 Bayer Healthcare Ag Substituierte Dihydropyridine
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
KR20070087602A (ko) 2004-12-13 2007-08-28 아이알엠 엘엘씨 화합물 및 스테로이드성 수용체 및 칼슘 채널 활성의조절제로서의 조성물
KR101280096B1 (ko) 2005-06-29 2013-06-28 컴퓨메딕스 리미티드 전도성 브리지를 포함하는 센서 어셈블리
DE102005034264A1 (de) 2005-07-22 2007-02-01 Bayer Healthcare Ag 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung
DE102006026585A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung
DE102006026583A1 (de) * 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung

Also Published As

Publication number Publication date
TWI474821B (zh) 2015-03-01
HK1140194A1 (en) 2010-10-08
US20140100243A1 (en) 2014-04-10
JP5752754B2 (ja) 2015-07-22
WO2008104306A2 (de) 2008-09-04
TWI415608B (zh) 2013-11-21
EP2132206B1 (de) 2015-04-01
LUC00260I2 (pt) 2025-04-25
CO6220951A2 (es) 2010-11-19
WO2008104306A3 (de) 2009-03-19
EP2132206A2 (de) 2009-12-16
GT200900230A (es) 2011-11-29
ES2540803T3 (es) 2015-07-13
HUS2200015I1 (hu) 2022-06-28
IL200060A (en) 2016-07-31
HUE026441T2 (en) 2016-06-28
UY30931A1 (es) 2008-09-30
US8436180B2 (en) 2013-05-07
CL2008000502A1 (es) 2008-06-13
BR122020008544B1 (pt) 2021-02-17
DK2132206T3 (en) 2015-07-06
TW201340968A (zh) 2013-10-16
SA08290071B1 (ar) 2012-11-03
CA2679232C (en) 2016-07-05
AU2008221071A1 (en) 2008-09-04
IL200060A0 (en) 2010-04-15
CY1116455T1 (el) 2017-03-15
DE102007009494A1 (de) 2008-08-28
DOP2009000205A (es) 2010-02-28
MA31245B1 (fr) 2010-03-01
CU20090148A7 (es) 2011-04-26
MY176873A (en) 2020-08-25
JP5367586B2 (ja) 2013-12-11
NZ579230A (en) 2012-04-27
SI2132206T1 (sl) 2015-08-31
PT2132206E (pt) 2015-08-04
HRP20150702T1 (hr) 2015-08-14
CN101641352B (zh) 2013-11-20
BR122020008544B8 (pt) 2021-07-27
RU2470932C2 (ru) 2012-12-27
NO2022013I1 (en) 2022-05-06
US20100136142A1 (en) 2010-06-03
FR22C1017I2 (fr) 2023-02-03
FR22C1017I1 (fr) 2022-06-17
NL301192I2 (nl) 2022-12-07
MY150748A (en) 2014-02-28
BRPI0808098B8 (pt) 2021-05-25
CA2679232A1 (en) 2008-09-04
UA102065C2 (en) 2013-06-10
ZA200905730B (en) 2010-10-27
PL2132206T3 (pl) 2015-08-31
HN2009001597A (es) 2012-01-16
AR065463A1 (es) 2009-06-10
MX2009008701A (es) 2009-08-27
UY38952A (es) 2021-08-31
LTPA2022512I1 (pt) 2022-07-11
TN2009000318A1 (en) 2010-12-31
TW200843755A (en) 2008-11-16
ECSP099581A (es) 2009-09-29
US9051316B2 (en) 2015-06-09
UY38953A (es) 2021-08-31
LTC2132206I2 (pt) 2024-12-27
CR10976A (es) 2010-01-13
JP2014012678A (ja) 2014-01-23
CY2022022I2 (el) 2023-01-05
PE20090724A1 (es) 2009-07-17
CY2022022I1 (el) 2023-01-05
RU2009135659A (ru) 2011-04-10
BRPI0808098B1 (pt) 2020-08-04
JO3018B1 (ar) 2016-09-05
KR101614164B1 (ko) 2016-04-20
PA8770101A1 (es) 2009-05-15
KR20090129992A (ko) 2009-12-17
JP2010519232A (ja) 2010-06-03
CN101641352A (zh) 2010-02-03
CU23874B1 (es) 2013-04-19
AU2008221071B2 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0821276A2 (pt) Produto, e, uso do produto
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI0821027A2 (pt) 4-(4-ciano-2-tioaril) dihidropirimidinonas e seu uso
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
BRPI0821668A2 (pt) Uso
BRPI0914536A2 (pt) tiadiazoliloxifenilamidinas e o uso destas como fungicidas
BRPI0913885A2 (pt) Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
BRPI1012861A2 (pt) catalisador, e, uso do catalisador
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
CU20100122A7 (es) 4-fenilpiran 3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenilciclohexan-1,3,5-trionas como herbicidas
FI20086250A0 (fi) Sieniendoglukanaasit, niiden valmistus ja käyttö
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0818641A2 (pt) Rótulo, e, uso do rótulo
BRPI0808846A2 (pt) fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
BRPI1006996A2 (pt) composição, método e uso
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
BRPI0813453A2 (pt) 3-ciclopropil-4-(3-tiobenzoil)pirazol e seu uso como herbicida.
BRPI0809684A2 (pt) Embalagem, e embalagem
BRPI0812833A2 (pt) 4-imidazolinas e seu uso como antidepressivos
EP2165712A4 (en) PHENOLIC EXTRACTS OF ALCOHOL SKIN CONTAINING PROCYANIDES, PROPELARGONIDINES AND PRODELPHINIDES AND METHOD FOR OBTAINING THE SAME
BRPI0921225A2 (pt) caixinha porta-remédio e seu uso.
BRPI0812340A2 (pt) Macrociclos e seus usos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)